Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
6.855
USD
|
+1.11%
|
|
+1.56%
|
+10.56%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
644
|
583.9
|
124
|
534.3
|
1,439
|
1,605
|
-
|
-
|
Enterprise Value (EV)
1 |
445.3
|
583.9
|
124
|
534.3
|
1,439
|
1,605
|
1,605
|
1,605
|
P/E ratio
|
-5.11
x
|
-6.16
x
|
-0.72
x
|
-6.79
x
|
-20.7
x
|
-20
x
|
57.9
x
|
8.98
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
122
x
|
77.1
x
|
12.3
x
|
10.2
x
|
11.6
x
|
6.53
x
|
4.05
x
|
2.71
x
|
EV / Revenue
|
122
x
|
77.1
x
|
12.3
x
|
10.2
x
|
11.6
x
|
6.53
x
|
4.05
x
|
2.71
x
|
EV / EBITDA
|
-7.26
x
|
-6.56
x
|
-0.88
x
|
-10.3
x
|
-29.7
x
|
-29.3
x
|
17.8
x
|
5.69
x
|
EV / FCF
|
-8.38
x
|
-7.14
x
|
-0.8
x
|
-7.62
x
|
-
|
-22
x
|
42.8
x
|
8.45
x
|
FCF Yield
|
-11.9%
|
-14%
|
-125%
|
-13.1%
|
-
|
-4.54%
|
2.34%
|
11.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
85,807
|
90,248
|
112,743
|
187,460
|
232,138
|
233,977
|
-
|
-
|
Reference price
2 |
7.505
|
6.470
|
1.100
|
2.850
|
6.200
|
6.860
|
6.860
|
6.860
|
Announcement Date
|
3/6/20
|
3/8/21
|
2/28/22
|
3/2/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5.281
|
7.571
|
10.1
|
52.16
|
124.5
|
245.7
|
396.2
|
593.1
|
EBITDA
1 |
-88.76
|
-88.96
|
-140.2
|
-51.86
|
-48.45
|
-54.69
|
90.2
|
282
|
EBIT
1 |
-91.26
|
-90.78
|
-154.3
|
-63.76
|
-63.28
|
-73.43
|
36.26
|
207.8
|
Operating Margin
|
-1,728.14%
|
-1,199.05%
|
-1,528.63%
|
-122.24%
|
-50.84%
|
-29.89%
|
9.15%
|
35.04%
|
Earnings before Tax (EBT)
1 |
-94.94
|
-94.31
|
-158.2
|
-67.2
|
-65.52
|
-81.5
|
28.81
|
199.9
|
Net income
1 |
-94.94
|
-94.31
|
-158.2
|
-67.21
|
-66.07
|
-80.51
|
28.79
|
192.4
|
Net margin
|
-1,797.77%
|
-1,245.71%
|
-1,566.46%
|
-128.85%
|
-53.08%
|
-32.77%
|
7.27%
|
32.45%
|
EPS
2 |
-1.470
|
-1.050
|
-1.520
|
-0.4200
|
-0.3000
|
-0.3429
|
0.1184
|
0.7637
|
Free Cash Flow
1 |
-76.81
|
-81.76
|
-154.4
|
-70.1
|
-
|
-72.84
|
37.52
|
190.1
|
FCF margin
|
-1,454.44%
|
-1,079.9%
|
-1,529.35%
|
-134.4%
|
-
|
-29.65%
|
9.47%
|
32.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
41.59%
|
67.41%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
130.33%
|
98.76%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/6/20
|
3/8/21
|
2/28/22
|
3/2/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.029
|
0.468
|
2.526
|
4.986
|
44.18
|
11.37
|
22.33
|
56.39
|
34.36
|
46.02
|
55.27
|
66.3
|
78.09
|
80.73
|
91.82
|
EBITDA
1 |
-31.45
|
-23.68
|
-22.73
|
-19.63
|
14.18
|
-23.15
|
-13.42
|
11.18
|
-23.69
|
-24.66
|
-18.78
|
-11.37
|
-3.785
|
-
|
-
|
EBIT
1 |
-35.27
|
-27.81
|
-26.22
|
-21.88
|
12.14
|
-26.06
|
-16.62
|
7.398
|
-27.99
|
-24.68
|
-22.62
|
-17
|
-9.139
|
-9.961
|
-2.145
|
Operating Margin
|
-3,427.89%
|
-5,941.67%
|
-1,037.81%
|
-438.83%
|
27.49%
|
-229.25%
|
-74.44%
|
13.12%
|
-81.44%
|
-53.62%
|
-40.93%
|
-25.64%
|
-11.7%
|
-12.34%
|
-2.34%
|
Earnings before Tax (EBT)
1 |
-36.23
|
-28.07
|
-26.93
|
-22.89
|
10.7
|
-26.76
|
-17.12
|
6.829
|
-28.47
|
-26.4
|
-24.83
|
-19.17
|
-11.35
|
-11.56
|
-3.742
|
Net income
1 |
-36.23
|
-28.07
|
-26.94
|
-22.89
|
10.7
|
-26.77
|
-17.12
|
6.629
|
-28.8
|
-26.52
|
-24.55
|
-19.01
|
-10.66
|
-11.77
|
-4.104
|
Net margin
|
-3,521.28%
|
-5,998.08%
|
-1,066.43%
|
-459.15%
|
24.21%
|
-235.49%
|
-76.66%
|
11.76%
|
-83.82%
|
-57.62%
|
-44.42%
|
-28.67%
|
-13.65%
|
-14.57%
|
-4.47%
|
EPS
2 |
-0.3100
|
-0.2100
|
-0.1900
|
-0.1400
|
0.0600
|
-0.1300
|
-0.0800
|
0.0300
|
-0.1200
|
-0.1100
|
-0.1055
|
-0.0816
|
-0.0442
|
-0.0380
|
0.004000
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/2/23
|
5/3/23
|
8/2/23
|
10/31/23
|
2/22/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
199
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-76.8
|
-81.8
|
-154
|
-70.1
|
-
|
-72.8
|
37.5
|
190
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-152%
|
-74.3%
|
-49.8%
|
-60.6%
|
33.5%
|
86.1%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.33
|
0.32
|
1.87
|
0.06
|
0.34
|
1.3
|
1.32
|
1.35
|
Capex / Sales
|
6.15%
|
4.28%
|
18.49%
|
0.11%
|
0.28%
|
0.53%
|
0.33%
|
0.23%
|
Announcement Date
|
3/6/20
|
3/8/21
|
2/28/22
|
3/2/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
6.86
USD Average target price
13.83
USD Spread / Average Target +101.59% Consensus |
1st Jan change
|
Capi.
|
---|
| +10.56% | 1.61B | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|